Table 6.
Status of patients with DM (n = 170)
| Type of DM, n (%) | ||
| Type 1 | 5 (3.0) | |
| Type 2 | 132 (79.5) | |
| Unknown | 29 (17.5) | |
| DM therapy, n (%) | ||
| Tablet | 106 (67.1) | |
| Insulin | 21 (13.3) | |
| Tablet + Insulin | 31 (19.6) | |
| Change in insulin dose during pandemic, n (%) | ||
| No | 49 (76.6) | |
| Increase | 8 (12.5) | |
| Decrease | 7 (10.9) | |
| Quit or decreased dose of meds during pandemic, n (%) | ||
| No | 139 (84.8) | |
| Yes, sometimes | 17 (10.4) | |
| Yes, mostly | 7 (4.3) | |
| Yes, always | 1(0.6) | |
| HbA1c, % ±SD | 6.5±1.4 | |
| Frequency of capillary glucose measurement during pandemic, n (%) | ||
| No, not know how to | 25 (15.1) | |
| No, no tool | 39 (23.5) | |
| Some days, once a day | 56 (33.7) | |
| Some days, 2–3 times/day | 23 (13.9) | |
| Every day, 1–2 times/day | 13 (7.8) | |
| Every day; >3 times/day | 10 (6) | |
| Hypoglycemia during pandemic, n (%) | ||
| No, never | 104 (68.4) | |
| Yes, rarely | 22 (14.5) | |
| Yes, sometimes | 24 (15.8) | |
| Yes, frequently | 1 (0.7) | |
| Yes, always | 1 (0.7) | |
| FBG, mg/dL, n (%) | ||
| <100 | 12 (8.4) | |
| 101–160 | 73 (51.4) | |
| >160 | 25 (17.6) | |
| PPBG, mg/dL, n (%) | ||
| <160 | 36 (25.2) | |
| 161–220 | 50 (35.0) | |
| >220 | 16 (11.2) | |
DM, diabetes mellitus; HbA1c, hemoglobin A1c; FBG, fasting blood glucose; PPBG, postprandial blood glucose.